Some on the Street predict Buy-worthy data — “free call options.”
BMO Capital analyst Do Kim initiated coverage on VBIV with an Outperform rating and $11 price target.
Kim considers VBI’s Phase III hepatitis B vaccine, Sci-B-Vac, “largely de-risked” and at a commercial advantage over GlaxoSmithKline plc (ADR) (NYSE: GSK)’s clinically inferior Engerix-B and Dynavax Technologies Corporation (NASDAQ: DVAX)’s Heplisav-B, whose safety profile posed early regulatory concerns. (See Kim's track record here.)
“We estimate WW peak sales of $677 million, with a 70 percent probability of success,” Kim said in a Wednesday note.
VBI’s early stage pipeline could lend additional, unfactored upside, according to BMO.
Kim projects “a rapid clinical path” for the VBI-1901 glioblastoma candidate to drive global peak sales of $1.5 billion, while expected efficacy improvement in the Phase I congenital cytomegalovirus vaccine, VBI-1501A, could yield $2.2 billion, the analyst said.
BMO's positive rating — which echoes the sentiment of the two other research firms covering the stock — catalyzed a 6.7-percent spike. At the time of publication, shares were trading at $4.28, up 2.6 percent off the open.
Where Does Zika Virus Vaccine Research Stand Now?
Vaccine Business The Gateway To Drug Stores Providing Profitable Primary Healthcare
Photo courtesy of the FDA.
Latest Ratings for VBIV
|Nov 2017||BMO Capital||Initiates Coverage On||Outperform|
|Nov 2017||Canaccord Genuity||Initiates Coverage On||Buy|
|Jul 2016||Ladenburg Thalmann||Initiates Coverage on||Buy|
View More Analyst Ratings for VBIV
View the Latest Analyst Ratings
See more from Benzinga
- Square's Bitcoin Feature Could Secure An 'Early Mover Position'
- Latest Tax Reform Bill From Senate GOP Seeks Repeal Of ACA Individual Mandate
- Jim Chanos Adds To Tesla Short, Thinks Musk Will Step Down By 2020
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.